➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Merck
Johnson and Johnson
Moodys
Mallinckrodt

Last Updated: April 11, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR VANCOCIN HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Vancocin Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00384527 Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease Terminated Romark Laboratories L.C. Phase 3 2006-12-01 The primary objective of the study is to demonstrate non-inferiority of nitazoxanide compared to vancomycin in resolving symptoms of Clostridium difficile-associated disease (CDAD).
NCT00428844 Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci Completed Cubist Pharmaceuticals LLC Phase 2 2007-01-01 This is a research study designed to look at the efficacy and safety of daptomycin given at a dose of 6 mg/kg or 8 mg/kg in subjects being treated for prosthetic hip or knee infections caused by Staphylococci. These types of bacteria are among the most common types of bacteria causing infections of prosthetic joints.
NCT00430937 Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections Terminated Novartis Pharmaceuticals Phase 3 2006-04-01 This study evaluated the efficacy and safety of daptomycin compared to vancomycin or teicoplanin for the treatment of complicated skin and soft tissue infections
NCT00695903 Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia Terminated Cubist Pharmaceuticals LLC Phase 2 2008-09-01 The overall goals of this study are to compare the safety and efficacy of daptomycin monotherapy 10 mg/kg/day and vancomycin monotherapy dosed to achieve vancomycin trough levels of 15 to 20 μg/mL for the treatment of methicillin-resistant S. aureus bacteremia (MRSA), including right-sided infective endocarditis (RIE).
NCT01198509 Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA) Completed Memorial Sloan Kettering Cancer Center N/A 2010-01-01 Rheumatoid arthritis (RA) is an inflammatory form of arthritis that causes joint pain and damage. RA attacks the lining of the joints (synovium), causing swelling that can result in aching and throbbing, and eventually deformity. Even though there have been many advances in the treatment of RA, psoriatic arthritis (PsA), and other inflammatory arthritis, doctors still do not know what causes this inflammation in joints. It is likely that RA occurs as a result of a complex combination of factors, including a person's genes; lifestyle choices, such as smoking and diet; and things in a person's environment, including bacteria or viruses. This study investigates the hypothesis that bacteria living in a person's mouth and/or intestinal tract are responsible, at least in part, for the development of Rheumatoid Arthritis. The investigators believe that by killing those bacteria with antibiotics, they might be able to understand how the immune system works and, maybe, what causes RA.
NCT01198509 Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA) Completed National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) N/A 2010-01-01 Rheumatoid arthritis (RA) is an inflammatory form of arthritis that causes joint pain and damage. RA attacks the lining of the joints (synovium), causing swelling that can result in aching and throbbing, and eventually deformity. Even though there have been many advances in the treatment of RA, psoriatic arthritis (PsA), and other inflammatory arthritis, doctors still do not know what causes this inflammation in joints. It is likely that RA occurs as a result of a complex combination of factors, including a person's genes; lifestyle choices, such as smoking and diet; and things in a person's environment, including bacteria or viruses. This study investigates the hypothesis that bacteria living in a person's mouth and/or intestinal tract are responsible, at least in part, for the development of Rheumatoid Arthritis. The investigators believe that by killing those bacteria with antibiotics, they might be able to understand how the immune system works and, maybe, what causes RA.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Vancocin Hydrochloride

Condition Name

Condition Name for Vancocin Hydrochloride
Intervention Trials
Clostridium Difficile Infection 4
Primary Sclerosing Cholangitis 3
Clostridium Difficile 3
Arthropathy of Knee Joint 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Vancocin Hydrochloride
Intervention Trials
Infection 7
Communicable Diseases 6
Diarrhea 4
Soft Tissue Infections 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Vancocin Hydrochloride

Trials by Country

Trials by Country for Vancocin Hydrochloride
Location Trials
United States 120
Canada 9
United Kingdom 6
France 4
Italy 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Vancocin Hydrochloride
Location Trials
Florida 8
Georgia 7
California 7
Texas 7
New York 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Vancocin Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Vancocin Hydrochloride
Clinical Trial Phase Trials
Phase 4 6
Phase 3 8
Phase 2/Phase 3 2
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Vancocin Hydrochloride
Clinical Trial Phase Trials
Recruiting 11
Completed 8
Terminated 5
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Vancocin Hydrochloride

Sponsor Name

Sponsor Name for Vancocin Hydrochloride
Sponsor Trials
Cubist Pharmaceuticals LLC 3
Mayo Clinic 3
Children's Hospital of Philadelphia 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Vancocin Hydrochloride
Sponsor Trials
Other 32
Industry 16
U.S. Fed 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
McKesson
Dow
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.